U.S. News & World Report recognized 23 UNLV programs, including 13 from the William S. Boyd School of Law, in its annual list of top graduate and professional schools.

Since the early 2000s, the advances in biomarker testing have allowed clinicians to detect and diagnose Alzheimer disease (AD) and other related dementias more accurately. Given that no single biomarker test alone has been proven to diagnose the condition, the available biomarkers are often used in conjunction. While biomarkers have become an important part of research and hold critical value in the future of AD drug development, there has been no consensus as to which biomarkers hold the most value.

Home to a shiny school of medicine and a developing “medical district,” Southern Nevada has bolstered its medical bona fides in recent years. For researcher Samantha John, the region’s diverse population was another key element drawing her here.

The National Institute of General Medical Sciences (NIGMS) of The National Institutes of Health (NIH) has awarded a grant expected to total $11.3 million to fund phase 2 of southern Nevada’s first Center of Biomedical Research Excellence (COBRE): The Center for Neurodegeneration and Translational Neuroscience (CNTN). The funding will allow for an additional five years of continued collaboration between Cleveland Clinic Lou Ruvo Center for Brain Health and the University of Nevada, Las Vegas (UNLV) to enhance neuroscience research infrastructure in southern Nevada. The award is co-led by Aaron Ritter, M.D., of the Lou Ruvo Center for Brain Health and Jefferson Kinney, Ph.D. of the Department of Brain Health at UNLV.

UNLV and the Cleveland Clinic Lou Ruvo Center for Brain Health have received an $11.3 million federal grant to continue their joint research into brain diseases.

UNLV and the Cleveland Clinic Lou Ruvo Center for Brain Health have received an $11.3 million federal grant for the next phase of their joint research into the causes of degenerative brain diseases such as Alzheimer’s and potential treatments.

Whether it’s their heart shape, their seductive coloring or just the fact they make such sweet company, strawberries often are associated with romance.

Whether it's their heart shape, their seductive coloring or just the fact they make such sweet company, strawberries often are associated with romance.

A recent proposal that Medicare only cover Aduhelm (aducanumab) for patients with Alzheimer’s disease who are enrolled in clinical trials is needlessly restrictive, and will prevent many people from accessing a medication that may be able to help them.

A 2021 research paper authored by Jeffrey Cummings, MD, ScD, and colleagues estimated the cumulative expenditures to fund Alzheimer disease (AD) clinical trials over the past quarter-century and highlighted the numerous failed attempts that continue to plague the field. Overall, excluding the recent approval of aducanumab (Aduhelm; Biogen), there have only been 5 drugs—all for symptomatic treatment only—that have achieved FDA approval for AD since 1995. An estimated $42.5 billion in private expenditures has been sunk into AD clinical trials since then, with phase 3 representing the highest stage for costs of research and development ($24.1B).

Expert clinicians offer their insight on costs of Alzheimer drug development, a new agent for generalized myasthenia gravis, migraine in the emergency department, educational sleep medicine “boot camps”, AES 2021, and more.

The director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada–Las Vegas detailed the steps necessary to lower wasted costs from Alzheimer disease drug development and improve regulatory success.